TABLE 1.
Circulating phospholipid fatty acid concentration, % of total fatty acids2 |
||||||||
Cohort | n | Age, y | Women, % | trans-16:1n–7 | total trans-18:1 | cis/trans-18:2 | trans/cis-18:2 | trans/trans-18:2 |
CARDIA | 1507 | 45.8 ± 3.4 | 53.3 | 0.056 ± 0.028 | 1.489 ± 0.632 | 0.048 ± 0.021 | 0.133 ± 0.053 | 0.030 ± 0.021 |
CHS | 2404 | 75.0 ± 5.1 | 61.6 | 0.190 ± 0.05 | 2.010 ± 0.71 | 0.080 ± 0.02 | 0.130 ± 0.05 | 0.050 ± 0.04 |
GOLDN | 793 | 48.3 ± 15.9 | 50.4 | 0.073 ± 0.029 | 1.442 ± 0.424 | 0.086 ± 0.023 | 0.097 ± 0.032 | 0.043 ± 0.024 |
HPFS | 1295 | 64.3 ± 8.6 | 0 | 0.137 ± 0.045 | 1.498 ± 0.639 | 0.116 ± 0.049 | 0.085 ± 0.043 | 0.014 ± 0.018 |
MESA | 707 | 61.6 ± 10.4 | 61.6 | 0.064 ± 0.027 | 1.493 ± 0.675 | 0.062 ± 0.021 | 0.135 ± 0.059 | 0.038 ± 0.023 |
NHS | 655 | 59.9 ± 6.5 | 100 | 0.152 ± 0.045 | 1.619 ± 0.711 | 0.176 ± 0.064 | 0.135 ± 0.055 | 0.087 ± 0.059 |
WGHS | 652 | 54.4 ± 6.5 | 100 | 0.055 ± 0.026 | 1.791 ± 0.527 | 0.089 ± 0.023 | 0.098 ± 0.048 | 0.033 ± 0.012 |
Values are means ± SDs unless otherwise indicated. CARDIA, Coronary Artery Risk Development in Young Adults Study; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; CHS, Cardiovascular Health Study; GOLDN, Genetics of Lipid-Lowering Drugs and Diet Network; HPFS, Health Professionals Follow-Up Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses’ Health Study; WGHS, Women's Genome Health Study.
Fatty acids were measured in erythrocyte membrane phospholipids (GOLDN, HPFS, and NHS) or plasma phospholipids (CARDIA, CHS, MESA, and WGHS).